The following table shows Vertex’s direct customers ... software subscriptions, the stock-based compensation expense, and depreciation and amortization of capitalized software and acquired ...

The following table shows Vertex’s direct customers ... software subscriptions, the stock-based compensation expense, and depreciation and amortization of capitalized software and acquired ...

Sprinklr has also recently incorporated ChatGPT and Google Vertex AI functionalities into ... (All data in the above charts is GAAP). For balance sheet results, CXM ended the quarter with $476.6 ...

CervoMed's stock soars 400% on promising dementia drug data. See more on insights, potential concerns, and what it means for ...

The patient also had an AC deficit on vHIT, reduced cVEMP thresholds and torsional nystagmus to vertex vibration ... of abnormal SOT scores for the three sensory inputs is provided in Table 3. Few ...

The forward-looking statements contained in this Press Release are based on the expectations, estimates and projections of management of Vertex as of the date of this Press Release unless ...

Vertex Pharmaceuticals Inc.’s new non-opioid painkiller is being placed on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug lists.

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $503.20, representing a -1.37% change from its previous close. Amicus Therapeutics (FOLD) reported earnings 30 days ago.

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...